Ulcerative colitis
Summary
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by
chronic mucosal inflammation of the rectum, colon, and cecum. Common symptoms include
bloody diarrhea, abdominal pain, and fever. Laboratory findings typically show elevated inflammatory
markers and the presence of autoantibodies (pANCA). Definitive diagnosis requires biopsies showing
abnormal colonic mucosa and characteristic histopathology. Aminosalicylic acid derivatives are the
mainstay of treatment, although severe episodes typically
require corticosteroids and immunosuppressants to achieve remission. In the case of distal colitis, some
drugs may be administered topically (e.g., via enema), whereas more proximal inflammation requires
systemic treatment. Proctocolectomy is curative and indicated for complicated UC or dysplasia. Individuals
with UC are predisposed to colorectal cancer and should thus undergo regular surveillance colonoscopy.
NOTES
FEEDBACK
Epidemiology
 Prevalence
o Approx. 600,000 adults in the U.S. are affected by UC [1]
o Ethnicity
 Higher in the white than in the black, Hispanic, or Asian populations
 Highest among individuals of Ashkenazi Jewish descent.
o Slightly higher in men than women [2]
 Peak incidence
o 15–35 years [3]
o Another smaller peak may be observed in individuals > 55 years [4]
References: [2][4][5]
Epidemiological data refers to the US, unless otherwise specified.
NOTES
FEEDBACK
Classification
Truelove and Witts severity index [6]
MAXIMIZE TABLETABLE QUIZ
Criteria
Mild
Moderate
Severe
Bowel movements/day
<4
4–6
>6
Blood in stools
Intermittent
Frequent
Continuous
Temperature
< 37.5°C (99.5°F)
≤ 37.8°C (99.68°F)
> 37.8°C (100.4°F)
Heart rate
< 90/min
≤ 90/min
> 90/min
Hemoglobin
> 11.5 g/dL
≥ 10.5 g/dL
< 10.5 g/dL
ESR
< 20 mm/h
≤ 30 mm/h
> 30 mm/h
Montreal classification of extent and severity of ulcerative colitis [7]
MAXIMIZE TABLETABLE QUIZ
Disease extent/severity
Localization/definition
E1: Ulcerative proctitis
Mucosal involvement limited to the rectum
E2: Leftsided/distal ulcerative colitis
Mucosal involvement limited to part of the
colorectum distal to the splenic flexure
E3: Extensive
ulcerative colitis/pancolitis
Mucosal involvement extends to the proximal of the splenic
flexure
S0: Clinical remission
No mucosal involvement, asymptomatic
S1: Mild ulcerative colitis
≤ 4 stools/day (with or without blood), no signs of systemic
illness, ESR normal
S2: Moderate ulcerative colitis
> 4 stools/day, only minimal signs of systemic illness
S3: Severe ulcerative colitis
≥ 6 stools/day with blood, heart rate ≥
90/min, temperature ≥ 37.5°C (99.5°F), Hb < 10.5 g/dL, ESR >
30 mm/h
NOTES
FEEDBACK
Pathophysiology
Pathogenesis
The exact mechanism is unknown but studies suggest that ulcerative colitis is the result of abnormal
interactions between host immune cells and commensal bacteria. [2][8]
 Dysregulation of intestinal epithelium: increased permeability for luminal bacteria
→ activation of macrophages and dendritic cells → antigen presentation to macrophages and
naive CD4+ cells leads to
o Secretion of pro-inflammatory cytokines (IL-6, IL-12, TNF-α) and chemokines (CXCL1, CXCL3,
and CXCL8) → recruitment of other immune cells (e.g., neutrophils) to the site
o Differentiation of naive CD4+ cells to Th2 effector cells
o Recruitment of NK cells
 Dysregulation of the immune system: upregulation of lymphatic cell activity in bowel walls (T
cells, B cells, plasma cells) → enhanced immune reaction and cytotoxic effect
on colonic epithelium → inflammation with local tissue damage (ulcerations, erosions, necrosis) in
the submucosa and mucosa
o Autoantibodies (pANCA) against cells of the intestinal epithelium
o Th2 cell-mediated response
 Pattern of involvement
o Ascending inflammation beginning in the rectum and spreading continuously proximally
throughout the colon
o Inflammation is limited to the mucosa and submucosa.
The rectum is always involved in UC!
Risk factors [2][4][8]
 Genetic predisposition (e.g., HLA-B27 association)
 Ethnicity (white populations, individuals of Ashkenazi Jewish descent)
 Family history of inflammatory bowel disease
 Episodes of previous intestinal infection



Increased fat intake (esp. saturated fat and animal fat)
Oral contraceptive intake
NSAIDs may exacerbate UC
Protective factors [2][8]
 Appendectomy
 Smoking has a protective effect
NOTES
FEEDBACK
Clinical features
Intestinal symptoms
 Bloody diarrhea with mucus
 Fecal urgency
 Abdominal pain and cramps
 Tenesmus
Extraintestinal symptoms
 Skeletal (most common extraintestinal manifestation of
ulcerative colitis): osteoarthritis, ankylosing spondylitis, sacroiliitis [9][10]
 Ocular: uveitis, episcleritis, iritis
 Biliary: primary sclerosing cholangitis (PSC)
o Rare for patients with UC to develop PSC, but up to 90% of all patients affected by PSC will
also be affected by UC.
 Cutaneous: erythema nodosum, pyoderma gangrenosum, aphthous stomatitis, pyostomatitis
vegetans (multiple aphthae and pustules of the oral mucosa)
 General: fatigue, fever
 In children/adolescents: growth retardation and delayed puberty
Primary sclerosing cholangitis (PSC) is often associated with inflammatory bowel disease, especially UC.
However, only around 4% of people with inflammatory bowel disease develop PSC!
For the characteristics of ulcerative colitis, think “ULCCCERS”: Ulcers, Large intestine, Continuous/Colon
cancer/Crypt abscesses, Extends proximally, Red diarrhea, Sclerosing cholangitis.
Course of the disease
 Chronic intermittent
o Most common course
o Exacerbation is followed by complete remission.
 Chronic continuous
o Complete remission does not occur.
o Severity of the disease varies.
 Acute fulminant
o Sudden onset
o Severe diarrhea, dehydration, shock
NOTES
FEEDBACK
Subtypes and variants
Backwash ileitis
 Definition: inflammation of the terminal ileum in the context of ulcerative colitis
 Epidemiology: affects approx. 10–20% of all patients diagnosed with ulcerative colitis
 Localization: typically affects an area a few centimeters proximal to the ileocecal valve
 Pathophysiology: the pathological mechanism is not fully understood.
 Differential diagnosis: Clinically, backwash ileitis is hardly relevant but its presence makes it harder
to differentiate ulcerative colitis from Crohn disease
References:[11]
NOTES
FEEDBACK
Diagnostics
Laboratory tests
 Blood
o ↑ ESR, ↑ CRP, leukocytosis
o Anemia
o Thrombocytosis in some cases
o ↑ Perinuclear ANCA (pANCA)
 Medium sensitivity but high specificity
[12][13]
No correlation between titer and disease activity
Serologic testing is not recommended for definitive diagnosis or exclusion of UC but
can support the diagnosis. [3]
o In case of concurrent PSC: elevated gamma-glutamyl transferase
Stool analysis
o Test for bacteria to rule out infectious causes.



[3]
o
Calprotectin and lactoferrin are indicators of mucosal inflammation.
Endoscopy
Endoscopy (e.g., colonoscopy) with histological examination is considered the best test to definitively
diagnose UC.
 Typical findings: See “Gross pathology” below.
 Pattern of disease involvement [3]
o Proctosigmoiditis: limited to the rectum, with possible sigmoid involvement
o Left-sided colitis: extends distally to the splenic flexure
o Extensive colitis: extends beyond the splenic flexure
 Recommendations [3]
o Evaluate the ileum to rule out Crohn disease
o Stepwise biopsy (for findings, see "Pathology" below)
o Colonoscopy is contraindicated in patients with acute flare because of the high risk of
perforation but should be performed once symptoms improve.
 Sigmoidoscopy may be considered as an alternative.
Observe caution in taking biopsies from patients with severe disease, as the risk of perforation is high.
Imaging [3][14]
Imaging studies may serve as useful adjunct diagnostic procedures for UC, particularly when it comes
to detecting complications.
 Radiography
o Plain radiography
 Typically normal in mild to moderate disease
 Findings
 Loss of colonic haustra (lead pipe appearance) may be seen in severe cases
 Massive distention in cases of toxic megacolon
Pneumoperitoneum in cases of perforation
o Barium enema radiography
 Able to detect very early changes
 Findings
 Granular appearance of the mucosa
 Deep ulcerations
 Loss of haustra
 Pseudopolyps that appear as filling defects
CT: Detection of bowel wall thickening is possible in severe disease.
MRI: can be helpful in assessing disease severity and extent of bowel wall involvement
Ultrasound: can detect bowel wall thickening (manifests with absent hyperechoic reflection from
the lumen)




References:[12][13][15]
NOTES
FEEDBACK
Pathology
Gross pathology
 Early stages
o Inflamed, erythematous, edematous mucosa
o Friable mucosa with bleeding on contact with endoscope
o Fibrin-covered ulcers
o Small mucosal ulcerations
o Loss of superficial vascular pattern
 Chronic disease
o Loss of mucosal folds
o Loss of haustra
o Strictures
o Deep ulcerations
o Pseudopolyps
 Raised areas of normal mucosal tissue that result from repeated cycles of ulceration
and healing
 Ulceration → formation of granulation tissue → deposition of granulation tissue
→ epithelization
 Morphologically resemble polyps but do not undergo neoplastic transformation
 Found in advanced disease
In ulcerative colitis, the extent of intestinal inflammation is limited to the mucosa and submucosa. In
contrast, Crohn disease shows a transmural pattern of intestinal involvement.
Histological findings
 Early stages
o Granulocyte (neutrophil) infiltration: limited to mucosa and submucosa
o Crypt abscesses: an infiltration of neutrophils into the lumen of intestinal crypts due to a
breakdown of the crypt epithelium
 Chronic disease
o Lymphocyte infiltration
o Mucosal atrophy
o Altered crypt architecture
Branching of crypts
Irregularities in size and shape
o Epithelial dysplasia
Noncaseating granulomas are seen in Crohn disease but are not a feature of ulcerative colitis!


NOTES
FEEDBACK
Differential diagnoses
Differential diagnosis considerations
 Crohn disease (see “Differential diagnostic considerations: Crohn disease and ulcerative colitis”)
 Exudative-inflammatory diarrhea
 Diverticular disease
 Appendicitis
 Ischemic colitis
 Infectious colitis
o C. difficile colitis
o Shigella dysenteriae
o Salmonella enterocolitis
o Escherichia coli colitis
o Campylobacter enterocolitis
o Yersiniosis
o Tuberculosis
o CMV colitis
 Radiation colitis
 Celiac disease
 Inflammatory diarrhea
Microscopic colitis
 Definition: An idiopathic form of colitis that is characterized by a normal macroscopic appearance
of bowel on colonoscopy and collagenous or lymphocytic infiltrates on microscopy.
 Forms: collagenous colitis and lymphocytic colitis
 Etiology: unknown
 Clinical findings
o Chronic, nonbloody, watery diarrhea for > 4 weeks
o Weight loss
o Abdominal pain
 Pathological findings
o Gross pathology: normal appearance
o Histology
 Collagenous colitis: proliferation of collagenous connective tissue
 Lymphocytic colitis: mainly lymphocytic infiltrates with
little/no proliferation of connective tissue
 Treatment
o Cease nonsteroidal anti-inflammatory drugs (NSAIDs may be a trigger for disease)
o Symptomatic therapy (e.g., loperamide for mild diarrhea)
o Corticosteroids
The differential diagnoses listed here are not exhaustive.
NOTES
FEEDBACK
Treatment
Initially, UC is treated conservatively with drugs to induce and maintain disease remission.
Curative proctocolectomy is generally indicated if medical therapy fails or complications arise.
General management
 Rehydration
 Supplementation of nutritional deficiencies (e.g., iron)
 Supplementation of nutrition: severe cases may warrant consideration of a feeding tube
or parenteral nutrition.
Medical therapy [3]
Supportive care
 Antidiarrheal agents (e.g., loperamide): can only be used in the absence of a flare
 Anticholinergic medication (e.g., propantheline, dicyclomine): relieves abdominal cramping
 NSAIDs, opioids, and anticholinergics should be avoided in severe disease.
Mild disease
 5-aminosalicylic acid derivatives (5-ASAs)
o Drugs
 Mesalamine
 Sulfasalazine
 Olsalazine (compound of two 5-ASA molecules)
o Mechanism of action
 5-ASA alone (mesalamine) or bound to sulfapyridine as a carrier (sulfasalazine)
 Sulfasalazine is activated by colon bacteria
 5-ASA: antiinflammatory, immunosuppressive
 Sulfapyridine: antibacterial
o Indications
 Ulcerative colitis
 Colitis component of Crohn disease
o Side effects
 Mesalamine
 GI irritation: nausea, diarrhea
 In rare cases: peripheral
neuropathy, myocarditis or pericarditis, myelosuppression
 Sulfasalazine
 Most of the side effects are caused by the sulfapyridine
component of sulfasalazine.
 GI irritation: nausea, diarrhea
 Headache, fatigue, malaise, depression
 Megaloblastic anemia and folate deficiency due to interference
with dihydropteroate synthase
 Immune thrombocytopenia [16]
 Transient oligospermia
 Sulfa drug: allergic reactions, sulfonamide toxicity
o
o
Drug interactions: coadministration of nephrotoxic
drugs (e.g. NSAIDs, aminoglycosides, lithium) → ↑ risk of renal impairment
Additional information
 Can be administered orally, as suppositories,
or as enemas
Sulfapyridine has proven to have beneficial effects in patients with rheumatic
disease.
 If no improvement or 5-ASA agents are not tolerated
o Topical corticosteroids (e.g., budesonide)
o Oral systemic corticosteroids
Moderate disease
 Oral and topical 5-ASAs
 Topical corticosteroids (e.g., budesonide) → systemic corticosteroids only if no response
 Anti-TNF therapy (adalimumab, golimumab, or infliximab)
 Vedolizumab (integrin receptor antagonist)
 Tofacitinib (JAK3 inhibitor)
Severe or refractory disease
 High-dose oral and topical 5-ASAs
 Systemic corticosteroids
 Anti-TNF therapy (e.g., adalimumab, golimumab, or infliximab)
 Calcineurin antagonists (e.g., cyclosporine, tacrolimus)
 Thiopurines (6-mercaptopurine, azathioprine) may be considered but are no longer recommended
as monotherapy due to lack of efficacy [3]
 Vedolizumab (integrin receptor antagonist)
 Tofacitinib (JAK3 inhibitor)
 Referral for surgical proctocolectomy (see below)
Systemic corticosteroids should only be used for the treatment of an active flare and are not
recommended as a maintenance medication for ulcerative colitis.
Surgical intervention
 Goal
o Curative approach with full recovery
o Reduce risk of colorectal cancer
 Indications
o Emergent: Acute complications despite adequate conservative management (e.g., toxic
megacolon, perforation, sepsis, uncontrolled bleeding, etc.)
o Elective: epithelial dysplasia, severe relapses, long-term dependence on steroids,
impairment of the patient's general condition
 Procedure: proctocolectomy with an ileal pouch-anal anastomosis (IPAA or J pouch)
o Resection of the entire colon and rectal mucosa while sparing the anal sphincters.
o Loops of small intestine (serving as the pouch) are used to create an
artificial rectum (reservoir for feces) and thus a continence-conserving connection between
the ileum and anus.
 Complications
o Anastomotic leak
o Pouchitis (↑ stool frequency, malaise, and possibly incontinence caused by bacterial
overgrowth)
In contrast to Crohn disease, ulcerative colitis can be cured surgically (proctocolectomy).

NOTES
FEEDBACK
Complications
 Gastrointestinal bleeding (both acute and chronic)
 Toxic megacolon
 Perforation → peritonitis (see “Gastrointestinal perforation”)
 Fulminant colitis: severe bowel inflammation that typically causes > 10 stools per day, lower
gastrointestinal bleeding, abdominal pain, and abdominal distention
 ↑ Risk of cancer (see ”Colorectal carcinoma”)
o Risk increases with increased duration and/or extent of disease (e.g., pancolitis).
o Risk is not significantly increased in patients with mild UC
o Prevention: Screening colonoscopy with biopsies every 1–3 years starting 8 years after the
initial diagnosis to screen for colorectal cancer
[3]


Colonic stricture
Amyloidosis